

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/521,738	11/01/2005	Benedicte Chazaud	0508-1125	9212
466 YOUNG & TH	7590 12/11/2007 IOMPSON		EXAMINER	
745 SOUTH 2:	745 SOUTH 23RD STREET		SCHUBERG, LAURA J	
2ND FLOOR ARLINGTON, VA 22202			ART UNIT	PAPER NUMBER
,			1657	-
			MAIL DATE	DELIVERY MODE
			12/11/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)		
		10/521,738	CHAZAUD ET AL.		
Office Action Summary		Examiner	Art Unit		
	·.	Laura Schuberg	1657		
Period f	The MAILING DATE of this communication or Reply		, ··		
WHI - Extraction - If N - Fail Any	HORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING ensions of time may be available under the provisions of 37 CF of SIX (6) MONTHS from the mailing date of this communication of period for reply is specified above, the maximum statutory per ure to reply within the set or extended period for reply will, by six reply received by the Office later than three months after the month patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNIC. R 1.136(a). In no event, however, may a replaced to the seriod will apply and will expire SIX (6) MONT tatute, cause the application to become ABA	ATION. ply be timely filed  "HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).		
Status					
1)	Responsive to communication(s) filed on	·			
2a)[_		This action is non-final.			
3)[	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposi	tion of Claims		-		
5) 6) 7)	Claim(s) 71-106 is/are pending in the application of the above claim(s) is/are with Claim(s) is/are allowed.  Claim(s) is/are rejected.  Claim(s) is/are objected to.  Claim(s) 71-106 are subject to restriction as	drawn from consideration.			
Applica	tion Papers				
9)[	The specification is objected to by the Exam	niner.			
10)[	The drawing(s) filed on is/are: a) =	accepted or b)  objected to b	y the Examiner.		
	Applicant may not request that any objection to	the drawing(s) be held in abeyanc	e. See 37 CFR 1.85(a).		
11)	Replacement drawing sheet(s) including the cor The oath or declaration is objected to by the	· · · · · · · · · · · · · · · · · · ·	•		
Priority	under 35 U.S.C. § 119				
	Acknowledgment is made of a claim for fore		119(a)-(d) or (f).		
	1. Certified copies of the priority docum		aliantia a No		
	<ul><li>2. Certified copies of the priority docum</li><li>3. Copies of the certified copies of the priority docum</li></ul>	-	· · · · · · · · · · · · · · · · · · ·		
	application from the International But		eceived in this National Stage		
*	See the attached detailed Office action for a	· · · ·	eceived.		
Attachme		_			
	ice of References Cited (PTO-892) Ice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Sui Paper No(s)/	mmary (PTO-413) /Mail Date		
3) 🔲 Info	rmation Disclosure Statement(s) (PTO/SB/08) er Nots)/Mail Date		ormal Patent Application		

Application/Control Number: 10/521,738

Art Unit: 1657

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 71-84, drawn to a method of treatment of a disease.

Group II, claim(s) 85-88, drawn to a method of preparation of a composition.

Group III, claim(s) 89-99, drawn to a pharmaceutical composition.

Group IV, claim(s) 100-101, drawn to a binary complex.

Group V, claim(s) 102-103, drawn to a process for preparing pharmaceutical compositions.

Group VI, claim(s) 104-106, drawn to a product containing macrophages or a macrophage conditioned medium and a first type of cells.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the technical feature that the groups have in common, a macrophage composition for treatment of diseases, is known in the prior art as taught by Klein et al (WO 00/45827).

The expression "special technical feature" refers to those features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art. Thus, a feature found in the prior art cannot be considered to be a special technical feature.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the

Application/Control Number: 10/521,738

Art Unit: 1657

requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura Schuberg whose telephone number is 571-272-3347. The examiner can normally be reached on Mon-Fri 8:00-4:30.

Art Unit: 1657

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571/272-1000.

Leon B Lankford, Jr Primary Examiner Page 4

Art Unit 16/5/1

Laura Schuberg